A Double-Blind, Double Dummy, Randomized, Phase 1b, Nitrofurantoin Controlled, Repeat Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Microbiological Response of GSK3882347 in Female Participants With Acute Uncomplicated Urinary Tract Infection
Latest Information Update: 31 Jan 2025
At a glance
- Drugs GSK 3882347 (Primary) ; Nitrofurantoin
- Indications Urinary tract infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 28 Jan 2025 Status changed from recruiting to completed.
- 21 Aug 2024 Planned End Date changed from 16 Jul 2024 to 17 Feb 2025.
- 21 Aug 2024 Planned primary completion date changed from 16 Jul 2024 to 29 Jan 2025.